For decades, the question of whether estrogen might shield the aging brain from dementia has lingered at the edge of medicine's understanding. A new study of more than 21,000 women, published in Neurology, adds a meaningful chapter to that inquiry: women who used estrogen-only hormone therapy after age 70 showed markedly fewer biological signs of Alzheimer's disease and were nearly 40 percent less likely to receive a dementia diagnosis. The researchers are careful to frame this as association rather than causation, and the gap between historical prescribing practices and today's protocols mean
Later-life estrogen therapy linked to lower dementia risk in new study
An association, not proof of prevention
Mark
Why does the timing of hormone therapy matter so much here? If it worked at 70, wouldn't it work at 50?
Mimi
That's the central puzzle. We don't know if starting therapy decades earlier would produce the same effect, or if something about aging itself changes how the brain responds. The women in this study were already old when they began—their brains were already shaped by 70 years of life. Starting at 50 is a completely different biological moment.
Mark
So this study is basically a historical artifact?
Mimi
Not quite. It's evidence that estrogen and the brain have some relationship we don't fully understand yet. But yes, you can't just take a finding from women in their 70s and assume it applies to women in their 50s. The biology could be entirely different.
Mark
What about the women who didn't take therapy—could something else explain why they had more Alzheimer's signs?
Mimi
That's the honest answer: we don't know. This is observational data. Women who took hormone therapy might have been healthier overall, or had better access to care, or different genetics. The researchers tried to account for some of that, but you can't control for everything.
Mark
Is there any reason to think estrogen-only therapy is safer than the combination?
Mimi
Earlier studies suggested the progestin component might increase dementia risk, which is why researchers looked only at estrogen alone here. But that's based on limited evidence too. The honest answer is we need more research—on the timing, the dose, the type of hormone, all of it.
Mark
So what happens next?
Mimi
Someone needs to design a study using modern protocols—women starting in their 50s, with current dosing, followed for decades. That's expensive and takes time. Until then, this study is a signpost, not a roadmap.
Le Pouls
- A study spanning decades of medical records and nearly 3,000 autopsies has found that estrogen-only hormone therapy used after 70 correlates with dramatically fewer Alzheimer's hallmarks in brain tissue.
- The tension is real: these results challenge current medical practice, which typically ends hormone therapy before age 60, leaving researchers uncertain how to apply historical data to modern patients.
- Among therapy users, nearly twice as many women showed no Alzheimer's pathology at autopsy compared to non-users — a gap striking enough to demand further investigation.
- Blood and spinal fluid biomarkers reinforced the autopsy findings, suggesting estrogen may slow the accumulation of amyloid plaques, a key driver of cognitive decline.
- Researchers and clinicians are urging restraint: the study proves association, not prevention, and new trials using current dosing and timing are needed before any recommendations can reach patients.
For decades, the question of whether estrogen might shield the aging brain from dementia has lingered at the edge of medicine's understanding. A new study of more than 21,000 women, published in Neurology, adds a meaningful chapter to that inquiry: women who used estrogen-only hormone therapy after age 70 showed markedly fewer biological signs of Alzheimer's disease and were nearly 40 percent less likely to receive a dementia diagnosis. The researchers are careful to frame this as association rather than causation, and the gap between historical prescribing practices and today's protocols means the findings cannot yet be translated into clinical guidance — but they open a door worth walking through carefully.
A study published this week in Neurology has found that women who used estrogen-only hormone therapy after age 70 showed significantly fewer signs of Alzheimer's disease and were less likely to be diagnosed with dementia — a finding that is both promising and complicated by the realities of how medicine has changed.
The research drew on two large datasets, tracking more than 21,000 women for three to five years beginning around age 71. In one group, brain tissue from nearly 3,000 autopsies revealed a striking pattern: 18 percent of hormone therapy users showed no Alzheimer's pathology whatsoever, compared to just 10 percent of non-users. Meanwhile, all three hallmarks of the disease — amyloid-beta plaques, tau tangles, and neuritic plaques — appeared together in 40 percent of users versus 51 percent of those who never took the therapy. After adjusting for age, genetics, education, and other factors, therapy users had 35 percent lower odds of showing Alzheimer's pathology at autopsy.
Living participants told a similar story through their blood and spinal fluid. Women on estrogen therapy showed biomarker patterns consistent with less amyloid accumulation and faced 39 percent lower odds of a clinical dementia diagnosis. The study focused exclusively on estrogen-only formulations, deliberately excluding combination therapies with progestin, which earlier research had linked to increased dementia risk.
But a significant caveat shapes everything. The women in this study began therapy around age 70 — far later than current medical guidelines recommend. Today, hormone therapy is typically started in the late 40s or early 50s and discontinued before 60, usually only for women who have had a hysterectomy. Lead author Jennifer Bruno of Stanford Medicine was direct about the gap: the historical data cannot be cleanly mapped onto modern prescribing practices, and more research using current dosing and timing is essential before any clinical recommendations can be made.
The study, supported by the National Institute on Aging, does not prove that estrogen prevents dementia. It proves that an association exists — and that the question deserves a more rigorous answer.
A study of more than 21,000 women published this week in Neurology suggests that taking estrogen-only hormone therapy after age 70 may be linked to a lower risk of developing dementia. The research, which examined medical records spanning decades, found that women who used the therapy showed fewer hallmarks of Alzheimer's disease in their brains and lower levels of amyloid buildup compared to those who never took it. But the researchers are careful to note what the data does and does not show: an association, not proof of prevention.
The study drew from two large datasets and tracked participants for roughly three to five years, beginning at an average age of 71. Researchers examined clinical test results from living participants and, in one group, brain tissue from nearly 3,000 autopsies performed at an average age of 82. Among the total cohort, 1,953 women had taken hormone therapy while 19,509 had not. The analysis focused exclusively on estrogen-only formulations—not combination therapies with progestin, which earlier research suggested might increase dementia risk.
The autopsy findings were striking. Among women who had used hormone therapy, 18 percent showed no signs of Alzheimer's disease in their brain tissue, compared to just 10 percent of non-users. Conversely, 40 percent of therapy users displayed all three hallmarks of the disease—amyloid-beta plaques, tau tangles, and neuritic plaques—versus 51 percent of those who never took the medication. After accounting for age, education, genetics, race, and hypertension, women who used hormone therapy had 35 percent lower odds of showing Alzheimer's pathology at autopsy.
Blood and spinal fluid tests from living participants told a similar story. Women on hormone therapy showed biomarker patterns suggesting less amyloid accumulation in the brain—a key indicator that the protein was not building up into damaging plaques. The therapy was also associated with 39 percent lower odds of receiving a clinical dementia diagnosis and reduced risk of memory problems or functional decline.
Yet a significant caveat shadows these findings. The women in this study began hormone therapy around age 70, decades after it would typically be prescribed today. Current medical practice calls for starting therapy in the late 40s or early 50s and discontinuing it before age 60, usually only for women who have had a hysterectomy. Jennifer Bruno, the study's lead author from Stanford Medicine, acknowledged the gap between the historical data and modern protocols. "While these findings help us better understand the relationship between hormone therapy use and various markers of dementia, more research needs to be done before we can make recommendations to women about their use of these therapies in relation to their brain health," she said. The timing and type of therapy used decades ago, she noted, differs substantially from what doctors prescribe now, making direct application to today's patients uncertain.
The study does not prove that hormone therapy prevents dementia—only that an association exists between its use and better brain health outcomes in this particular population. Researchers emphasize that additional work is needed, ideally using current dosing and timing protocols, before any clinical recommendations can be made. The findings were supported by the National Institute on Aging.
Citations marquantes
While these findings help us better understand the relationship between hormone therapy use and various markers of dementia, more research needs to be done before we can make recommendations to women about their use of these therapies in relation to their brain health.— Jennifer Bruno, study author, Stanford Medicine
Envie de l'histoire complète ?
Lire l'original sur News-Medical ↗
Health & Medicine